VEITH 2021: PROMISE I shows CLTI Patients Gain Greater Freedom From Amputation With LimFlow System

Подробнее о видео

Watch the full video on Radcliffe Vascular here:

The PROMISE I trial was designed to evaluate the use of the LimFlow Stent Graft System, a deep vein arterialisation device intended for patients with advanced peripheral artery disease, desert foot. Initially discussed at VEITHsymposium 2021, Dr Peter Schneider (University of California, San Francisco, CA, US) reveals the outcomes of this trial, which suggest that the LimFlow System promotes greater freedom from amputation in patients with critical limb ischaemia.

Discussion points:
1. The LimFlow Stent Graft System
2. LimFlow Procedure
3. Key Findings of Promise I
4. Further Research Required

Filmed remotely from San Francisco, 2021.
Interviewer: Jordan Rance

This content is intended for healthcare professionals only.

Radcliffe Cardiology is a dynamic, digitally-focused producer & publisher of Cardiovascular, Renal and Metabolic (CVRM) content for physicians worldwide. We aim to assist in the continuous education of physicians within the cardiology fraternity, generating a range of clinical content through collaboration with leading cardiologists from around the globe.